FDA Determines Regulatory Review Period for SYNRIBO Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for SYNRIBO, a human drug product, as required by law, following a submission to the US Patent and Trademark Office (USPTO) for patent extension.